Moderna says COVID-19 vaccine could be approved in December
Stéphane Bancel, chief executive of Moderna Inc., said Monday that the federal government could grant emergency use authorization for its COVID-19 vaccine in December, assuming the company gets promising data from its Phase 3 trial in November. Moderna started its final-phase trial with 30,000 volunteers in July, and in order to apply for emergency authorization, 53 of the subjects have to become infected with the new coronavirus, and the cases have to be significantly higher in the half of the trial that received a placebo.
That first analysis will likely happen in November, Bancel said at a Wall Street Journal conference, but "it's hard to predict exactly which week because it depends on the cases, the number of people getting sick." If the results don't show sufficient efficacy, Moderna will try again when 106 trial participants contract symptomatic COVID-19, likely delaying authorization until early next year. Under Food and Drug Administration guidelines, drugmakers also have to show that their vaccine is safe for at least two months after vaccination, a benchmark Bancel said Moderna should hit in late November.
Moderna is testing one of four viable COVID-19 vaccines, and its timeline is closest to Pfizer, which said last week it expects to seek emergency use authorization of its vaccine in late November. The trials of vaccine candidates from Johnson & Johnson and AstraZeneca are on pause while the companies look into unexplained health issues among participants. Moderna says it plans to produce 20 million does of its vaccine this year and 500 million next year.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Indie film's 'very brief' use of AI sparks backlash and calls for boycotts
Talking Points Did the creators of a new horror movie make a deal with the artificial intelligence devil?
By Rafi Schwartz, The Week US Published
-
Could Taylor Swift swing the election?
Today's Big Question The pop star has outsized influence — and that extends beyond the music industry
By Anya Jaremko-Greenwold Published
-
Kevin Hart awarded Mark Twain Prize
Speed Read He is the 25th recipient of the prestigious comedy prize
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published